3b Blackbio Dx Ltd · NSE:3BBLACKBIO
3b Blackbio Dx — Kilpest India — Investor Presentation (February 2017)
19 slides from 3b Blackbio Dx's investor presentation, Feb 6, 2017
Slide 1: Cover letter to BSE
; REGD. OFFICE & FACTORY : SUREWIN QUALITY CERTIFICATION 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL - 462 023 (INDIA) §SO 9001 : 2000 : KILPEST INDIA LIMITED Cc s-c Tel : (91-755) 2586536, 2586537, 2586439 FAXNO. : (91-755) 2580438 Email : kilpest@bsnl.in visit us at : www.kilpest.com kilpestbpl|@yaho
Slide 2: Investor Presentation January 2017
Farmers trusted Agro-input partner for 44 years Reliable & affordable healthcare diagnostics solutions INVESTOR PRESENTATION January 2017
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Kilpest India Limited and 3B BlackBio Biotech India Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to
Slide 4: Kilpest Existing Products
Kilpest Existing Products Chemicals Biologicals No. of Products No. of Products • Insecticides - 70 • Bio pesticide - 07 • Antibacterials - 01 • Bio fungicide - 01 • Fungicides - 15 • Bio fertilizers - 05 • Herbicides - 11 • Bio nematicides - 01 • Public Health - 11 • Public Health - 02 • Microferti
Slide 5: Business Overview and Strengths
Business Overview and Strengths • 44yrs old Pesticide Formulation Company, well established in central India, strong brand equity in central India especially in Madhya Pradesh and Chhattisgarh. • Strong distribution reach through depot and dealers in Central India. • Company continuously developing
Slide 6: Financial Performance: Key Highlights
Financial Performance : Key Highlights 9M FY17, KILPEST (Consolidated) Q3 FY17 9M FY17 FY16 1316.45 2.61% 9M FY17, 129.76% Net sales 439.19 1316.45 1732.72 103.56 9M FY16, Profit before tax 24.09 127.86 43.69 9M FY16, 1282.93 44.55 Profit after tax 19.51 103.56 33.49 Paid up Equity share capital 640
Slide 7: The Economic Times: Pesticide Manufacturers Suffer Lower Sales, Profits
THE ECONOMIC TIMES | INDORE/BHOPAL | WEDNESDAY | 25 JANUARY 2017 Pesticide Manufacturers Suffer Lower Sales, Profits Cos forced to cut production as lower temperatures and humidity make crops resistant to pest attacks after several years Ashish.kulshrestha @timesgroup.com Hyderabad: Goodmonsoon may
Slide 8: Company Overview
Company Overview Although the financials for agrochemical alone have been affected due to reasons mentioned in above newspaper clipping (due to lower pest infestation) this year. However, the company hopes to do better in coming year with its thrust on plant growth products (which are not affected b
Slide 9: Financial Highlights - 3B BlackBio Biotech (9M FY17)
Financial Highlights- 3B BlackBio Biotech (9M FY17) 9M FY17, 222.06 9M FY17, 85.03% 119.38 366.87% 9M FY16, 120.01 9M FY16, 25.57 Revenue EBITDA 9M FY17, 9M FY17, 92.01 74.54 360.05% 375.08% 9M FY16, 9M FY16, 20 15.69 PBT PAT Rs. In Lakhs
Slide 10: Margin Profile - 3B BlackBio Biotech (9M FY17)
Margin Profile- 3B BlackBio Biotech (9M FY17) 9M FY17, 9M FY17, 57.96% 53.76% 9M FY16, 9M FY16, 51.74% 21.30% Value Addition* EBITDA Margin 9M FY17, 47.58% 9M FY17, 33.57% 9M FY16, 20.39% 9M FY16, 13.07% EBIT Margin PAT Margin Rs. In Lakhs *Revenue (-) cost of raw materials consumed (-) change in in
Slide 11: Financial Highlights - 3B BlackBio Biotech (Q3 FY17)
Financial Highlights- 3B BlackBio Biotech (Q3 FY17) Q3 FY17, 39.3% 73.86 Q3 FY17, 142.85% Q3 FY16, 30.6 53.02 Q3 FY16, 12.6 Revenue EBITDA Q3 FY17, Q3 FY17, 112.03% 127.54% 19.38 15.7 Q3 FY16, Q3 FY16, 9.14 6.9 PBT PAT Rs. In Lakhs
Slide 12: Margin Profile - 3B BlackBio Biotech (Q3 FY17)
Margin Profile- 3B BlackBio Biotech (Q3 FY17) Q3 FY16, 48.26% Q3 FY17, 41.43% Q3 FY16, Q3 FY17, 23.76% 43.47% Value Addition* EBITDA Margin Q3 FY17, Q3 FY17, 32.76% 21.25% Q3 FY16, Q3 FY16, 23.21% 13.01% EBIT Margin PAT Margin Rs. In Lakhs *Revenue (-) cost of raw materials consumed (-) change in in
Slide 13: Industry Potential - Molecular Diagnostics
Industry Potential- Molecular Diagnostics The global IVD Market US$ 54.7 billion in the year 2015 (CAGR of 5-6%)1 Molecular Diagnostic Market US$ 7 billion (CAGR of 10-15%)2 Indian diagnostics industry was around Rs. 377 billion in 2014-2015 and will continue to grow by a CAGR of 16%-17% over the ne
Slide 14: Demand drivers for the Indian Diagnostic Industry
Demand drivers for the Indian Diagnostic Industry • Increased focus on advanced diagnostics • changing costs and quality of healthcare, • rising medical tourism, • evolution of disease profiles, • technology as a driving force, • increase in evidence-based treatments / Drug response monitoring • cha
Slide 15: Molecular Diagnostics
Molecular Diagnostics The process of identifying a disease by studying molecules, such as proteins, DNA, and RNA, in a tissue or fluid. Molecular diagnostics is a technique used to analyze biological markers in the genome and proteome—the individual’s genetic code and how their cells express their g
Slide 16: Our Positioning and Value Creation
Our Positioning and Value Creation • As per research, the Indian diagnostic market is expected to grow at CAGR 20 per cent to $32 billion between 2012- Increasing 2022, from $5 billion in 2012.1 market • Rapid, accurate and actionable molecular diagnostics are needed for effective management of dise
Slide 17: Winning Strategy
Winning Strategy Proprietary kits designed, developed & validated in-house Well accepted assays across wide customer base PAN India Continuous R&D initiatives for International quality product Wide range of Diagnostic kits- Infectious, Oncology & Genetics Import substitution with price advantage and
Slide 18: PCR based Molecular Diagnostic Kit Range
PCR based Molecular Diagnostic Kit Range Genetics & Oncology TRUPCR® BCR-ABL Qualitative Kit – M m µ Detection and differentiation of BCR-ABL major (M), minor (m) and micro (µ) transcripts TRUPCR® BCR-ABL Quantitative Kit – M m µ Detection, differentiation and quantitation of BCR-ABL major (M), mino
Slide 19: For further information, please contact
For further information, please contact: KILPEST INDIA LIMITED 3B BLACKBIO BIOTECH INDIA LIMITED 7-C Industrial Area , Govindpura, Bhopal- 462023[M.P.] INDIA 7-C Industrial Area , Govindpura, Bhopal- 462023 [M.P.] INDIA Phone :: +91-755-2586536 Phone :: +91-755-4077847 Fax :: +91-755-2580438 Fax ::
Kilpest India — Investor Presentation (February 2017) on 6ix